Table 2.
KEGG pathway enrichment analysis for the deregulated miRNA target set
| KEGG_Subcategory | Expected | Observed | P value (FDR) | miRNAs | miRNA expression | Target genes |
|---|---|---|---|---|---|---|
| MAPK signaling pathway | 8.49658 | 21 (up) | 0.00300 | miR-96 | ↑ | PPP3R1, MAP2K1, CACNB4 |
| miR-222 | ↑ | PPP3R1, NTF3, NLK | ||||
| miR-21 | ↑ | NTF3 | ||||
| miR-221 | ↑ | NLK | ||||
| miR-106b | ↑ | MAP3K2, CRK, DUSP2, RPS6KA5, MAP3K14 | ||||
| miR-214 | ↓ | CRK | ||||
| miR-155 | ↑ | MAP3K14, FGF7 | ||||
| miR-34a | ↓ | CACNB3, RRAS, PDGFRA | ||||
| miR-195 | ↓ | FGF7, CACNB1 | ||||
| miR-183 | ↑ | MEF2C, MAP3K4, NTRK2, MAPK8IP1 | ||||
| miR-199a-3p | ↓ | MAP3K4 | ||||
| miR-182 | ↑ | RASA1 | ||||
| Metabolic | 35.6411 | 17 (up) | 0.00300 | miR-34a | ↑ | FUT8, GALNT7, NDST1, ACSL4, GLCE, ACSL1 |
| miR-214 | ↓ | GALNT7 | ||||
| miR-224 | ↑ | ACSL4 | ||||
| miR-186 | ↑ | ACSL4, BCAT1 | ||||
| miR-155 | ↑ | UPP2, BCAT1 | ||||
| miR-183 | ↑ | IDH2, GPAM, AMD1, MTMR6, SMPD3 | ||||
| miR-195 | ↓ | PISD | ||||
| miR-96 | ↑ | ABAT, GALNT2, EXT1 | ||||
| TGFβ (down-regulated) | 2.7049 | 11 | 0.00300 | miR-96 | ↑ | E2F5 |
| miR-106b | ↑ | E2F5, BMPRII, RBL2, ZFYVE9, RBL1, SMAD7 | ||||
| miR-34a | ↓ | E2F5, ACVR2B | ||||
| miR-21 | ↑ | SMAD7 | ||||
| miR-155 | ↑ | GDF6, SP1 | ||||
| miR-183 | ↑ | PPP2CA, PPP2C | ||||
| Oocyte meiosis | 3.62775 | 12 | 0.00532 | miR-96 | ↑ | PPP3R1, ITPR1, ITPR2, MAP2K1, FBXW11 |
| miR-34a | ↓ | CCNE2 | ||||
| miR-155 | ↑ | YWHAZ | ||||
| miR-183 | ↑ | PPP2CA, PPP2CB | ||||
| miR-195 | ↓ | BTRC | ||||
| miR-222 | ↑ | PPP3R1 | ||||
| miR-214 | ↓ | YWHAZ | ||||
| Wnt signaling pathway (up-regulated 88% of genes) | 4.80518 | 14 | 0.00532 | miR-96 | ↑ | PPP3R1, FBXW11 |
| miR-222 | ↑ | PPP3R1, NLK | ||||
| miR-106b | ↑ | NFAT5, ANGL1 | ||||
| miR-34a | ↓ | DAAM1, FOSL1, LEF1 | ||||
| miR-155 | ↑ | CSNK1A1 | ||||
| miR-183 | ↑ | PPP2CA, LRP6, PPP2CB | ||||
| miR-195 | ↓ | BTRC, AXIN2 | ||||
| miR-221 | ↑ | NLK | ||||
| miR-186 | ↑ | NFAT5 | ||||
| Axon guidance (up-regulated) | 4.10509 | 12 | 0.01178 | miR-96 | ↑ | PPP3R1 |
| miR-221 | ↑ | GNAI3 | ||||
| miR-106b | ↑ | NTN4, DPYSL5, EPHA4, NFAT5, CFL2, LIMK1, DPYSL2 | ||||
| miR-155 | ↑ | SEMA5A | ||||
| miR-182 | ↑ | RASA1 | ||||
| miR-224 | ↑ | ARHGEF12, DPYSL2 | ||||
| miR-222 | ↑ | PPP3R1 | ||||
| miR-96 | ↑ | NTN4 | ||||
| miR-183 | ↑ | EPHA4 | ||||
| miR-186 | ↑ | NFAT5 | ||||
| Regulation of actin cytoskeleton (mostly up-regulated, 84% of genes) | 6.87364 | 16 | 0.01739 | miR-106b | ↑ | ITGB8, CRK, PFN2 SSH2,CFL2, LIMK1 |
| miR-34a | ↓ | RRAS, PDGFRA | ||||
| miR-214 | ↓ | CRK | ||||
| miR-183 | ↑ | PFN2, TMSL3, TMSB4X, ENAH | ||||
| miR-155 | ↑ | FGF7 | ||||
| miR-195 | ↓ | FGF7 | ||||
| miR-122a | ↓ | GIT1 | ||||
| miR-224 | ↑ | ARHGEF12 | ||||
| miR-96 | ↑ | MAP2K1, FN1 | ||||
| Prostate cancer (up-regulated) | 2.83219 | 9 | 0.02272 | miR-222 | ↑ | CDKN1B |
| miR-106b | ↑ | E2F1, CDKN1A | ||||
| miR-34a | ↓ | CCNE2, LEF1, PDGFRA | ||||
| miR-182 | ↑ | BCL2 | ||||
| miR-96 | ↑ | CREB3L2, MAP2K1 | ||||
| Cell cycle | 4.07327 | 11 | 0.02474 | miR-222 | ↑ | CDKN1B, CDKN1C |
| miR-96 | ↑ | E2F5 | ||||
| miR-106b | ↑ | E2F5, RBL2, WEE1, E2F1, RBL1, CDKN1A | ||||
| miR-34a | ↓ | E2F5, CCNE2 | ||||
| miR-155 | ↑ | WEE1, YWHAZ | ||||
| miR-214 | ↓ | YWHAZ | ||||
| miR-21 | ↑ | STAG2 | ||||
Note: This table was generated using the GeneTrail enrichment for the miRNA targets on the KEGG database. Expected indicates the random effect of the targets in the pathway and observed means the actual effect of the targets in the pathway.